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A selective cyclooxygenase-2 inhibitor decreases proteinuria Prostaglandins arise from enzymatic metabolism of
and retards progressive renal injury in rats. arachidonic acid by prostaglandin G2/H2 synthase (cyclo-
Background. We have previously shown that cyclooxygen- oxygenase) and further metabolism by specific synthe-
ase-2 (COX-2) expression is low in the renal cortex of adult
tases [1]. The kidney is a particularly rich source forrats, but is increased in macula densa/cortical thick ascending
prostaglandins, and prostaglandins modulate a broadlimb and in glomerular podocytes after subtotal renal ablation.
range of renal functions, including both hemodynamicsMethods. To evaluate the functional consequences of this
increased COX-2 expression, male rats were subjected to sub- and water and solute reabsorption. Cellular responses
total renal ablation and divided into four groups: (1) treatment are mediated by specific membrane-associated receptors,
with the selective COX-2 inhibitor SC58236, (2) treatment with which are members of the G-protein–coupled receptorvehicle, (3) treatment with the angiotensin-converting enzyme
superfamily. Since receptor affinity for the prostanoidsinhibitor enalapril, and (4) treatment with enalapril 1 SC58236.
is in the nanomolar range, prostanoids act locally onThe administration of drugs was begun on the third day after
ablation and continued for 6 to 10 weeks. the tissues in which they are synthesized or on tissues
Results. Within one week after ablation, vehicle-treated rats adjacent to those in which they are formed [2].
developed hypertension. Although enalapril led to significant The gene for constitutive cyclooxygenase (COX-1) en-
reductions in blood pressure, either alone or in combination
codes a 2.7 to 2.9 kb transcript [3]. In the normal adultwith the COX-2 inhibitor, SC58236 alone did not significantly
kidney, immunoreactive COX-1 has been localized toalter ablation-induced hypertension. However, the SC58236-
arteries and arterioles, glomerular mesangium, and col-treated animals exhibited levels of proteinuria at six weeks
after ablation that were comparable to those seen with enalapril lecting duct epithelium. No immunoreactive COX-1 has
(vehicle, 47 6 4 ; enalapril, 27 6 2; SC58236, 30 6 2 mg/day; been found in the proximal or distal convoluted tubules,
N 5 7, P , 0.01, each group compared with vehicle), and Henle’s loop, or macula densa [4, 5]. In addition to consti-continued SC58236 treatment led to persistent reductions in
tutive COX-1, an inducible and glucocorticoid-respon-proteinuria at 10 weeks after renal ablation (vehicle, 77 6 4;
sive isoform, COX-2, increases in response to mitogenicSC58236, 50 6 4 mg/day; N 5 6, P , 0.01). SC58236 treatment
also significantly reduced the percentage of glomeruli exhib- and inflammatory stimuli and mediates prostanoid pro-
iting segmental or global sclerosis at 10 weeks (32.6 6 7.8% duction from arachidonic acid released by endotoxin or
vs. 10.9 6 2.8%, N 5 6, P , 0.03). Furthermore, SC58236 mitogens [6–10]. The selective expression of COX-2 in
treatment partially inhibited increases in transforming growth
response to inflammation and the recognition that COX-1factor-b1 mRNA expression and increases in collagen III and
is the only cyclooxygenase isoform expressed in normalcollagen IV mRNA expression.
gastric mucosa have provided the impetus for the devel-Conclusions. These studies indicate that chronic treatment
with a specific COX-2 inhibitor may retard the progression of opment of selective COX-2 inhibitors.
progressive renal injury, and suggest that such compounds can In addition to inflammatory states, our previous stud-
be used in combination with angiotensin-converting enzyme ies have indicated that the normal adult rat kidney has
inhibitors. Further studies are required to determine the mech-
low but measurable levels of COX-2 mRNA, which isanism by which COX-2 inhibition is renoprotective.
localized to scattered cortical thick ascending limb cells
in the region of the macula densa and to a subset of
medullary interstitial cells in the papilla [5]. In animalsKey words: glomerulosclerosis, renal failure, macula densa, tubuloin-
terstitium. chronically salt depleted, COX-2 expression in the peri-
macula densa region increases significantly [5, 11, 12].Received for publication June 3, 1999
In addition, we have recently demonstrated selectiveand in revised form December 17, 1999
Accepted for publication January 21, 2000 increases in renal cortical COX-2 expression following
subtotal renal ablation [13]. Since cyclooxygenase me-Ó 2000 by the International Society of Nephrology
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tabolites have been reported to be among the mediators previously [23]. RNA samples were electrophoresed in a
of altered renal function and glomerular damage follow- denatured agarose gel and transferred to nitrocellulose
ing subtotal renal ablation [14–19], the current studies membranes and hybridized with a 1.4 kb 32P-labeled Bam
were designed to determine the effect of chronic admin- HI/Hind III cDNA fragment of rat renin, a 2.2 kb PvuII
istration of a selective COX-2 inhibitor on the progres- cDNA fragment of rat pro-a1(III) collagen, a 0.62 kb
sion of renal injury following subtotal ablation. PstI-PvuII cDNA fragment of mouse a1(IV) collagen or
a 2.0 kb EcoRI cDNA fragment of human transforming
growth factor-b1 (TGF-b1). The membranes were thenMETHODS
stripped and rehybridized with glyceraldehyde-3-phos-
Sprague-Dawley rats were from Harlan (Indianapolis, phate dehydrogenase.
IN, USA). 32P-CTP (3000 Ci/mmol) was from Amersham All values are presented as mean 6 SEM. Analysis
(Arlington Heights, IL, USA). The selective COX-2 in- of variance (ANOVA) and Bonferroni t-tests, paired
hibitor SC58236, which exhibits a COX-2/COX-1 selec- t-test, and simple regression were used for statistical anal-
tivity of 1780-fold [20], was a gift from Searle Monsanto ysis, and differences were considered significant when
Co. (St. Louis, MO, USA). Other reagents were pur-
P , 0.05.
chased from Sigma Chemical Co. (St. Louis, MO, USA).
Male Sprague-Dawley rats, initially weighing 150 to
200 g, were used. For ablation of renal mass, animals were RESULTS
anesthetized with ketamine:xylazine (9:1) and placed on Three days following subtotal renal ablation, daily ga-
a warming table, and their kidneys were exposed under vage was initiated with SC58236, which has a COX-2/
aseptic conditions via a ventral abdominal incision. The COX-1 selectivity of at least 1780-fold, or methylcellu-
right kidneys were removed, and the posterior and ante- lose vehicle and was continued for 6 or 10 weeks.
rior (if present) apical segmental branches of the left SC58236 has a long plasma half-life in rats (117 h) [20],
renal artery were individually ligated, as described [21].
which allowed the administration of a single daily dose.
Following renal ablation, rats were divided into four
The plasma level of the drug in the subtotally nephrecto-groups. Group 1 was gavaged daily for six weeks with
mized rats at the end of 10 weeks was 7.78 6 1.27 mg/mL,SC58236 (10 mg/kg/day in 1% methylcellulose), begin-
a value similar to plasma levels in rats with normal kid-ning on the third day following surgery, while group
neys (K. Seibert, personal communication) [20]. In addi-2 was gavaged with the methylcellulose vehicle alone.
tion, other animals subjected to renal ablation wereGroup 3 was administered enalapril in the drinking water
treated with enalapril, with or without SC58236, for six(20 mg/kg body weight per day), and group 4 was gavaged
weeks. There was no mortality in any of the groupswith SC58236 daily and was administered enalapril. Ad-
during the treatment period. There were no differencesditional subsets of group 1 and group 2 were gavaged
in increases in body weight among the four experimentaldaily for 10 weeks.
groups for six weeks following renal ablation (Fig. 1A).Blood pressure (BP) was measured every week with
In addition, body weight was not different between ani-a tail-cuff microphonic manometer, as previously de-
mals treated with vehicle or SC58236 for 10 weeks (vehi-scribed [22]. Twenty-four–hour urinary protein samples
cle, 373 6 3 g; SC58236, 370 6 4 g; N 5 6, P 5 NS).were collected weekly and measured by BCA protein
Hematocrits were also not different between vehicle-Assay Reagent kit (Pierce, Rockford, IL, USA). Blood
and SC58236-treated rats after 10 weeks of treatmenturea nitrogen (BUN) was determined by standard diace-
(vehicle, 44.8 6 2.8; SC58236, 40.8 6 1.7; N 5 4, P 5 NS).tyl monoxime techniques, and creatinine was determined
BUNs were not different among the four experimentalby colorometric techniques (Sigma Chemical Co.). At
groups during the six weeks of observation (Fig. 1B) northe end of 6 or 10 weeks, animals were sacrificed. Kidneys
were BUNs or creatinine different between vehicle- andwere fixed in 10% formalin and were embedded with
SC58236-treated rats at 10 weeks (BUN: vehicle, 48.8 6paraffin, and 4 mm slides were cut and stained with hema-
4.8 mg/dL; SC58236, 57.5 6 5.2 g; N 5 6, P 5 NS;toxylin and eosin, periodic acid-Schiff, and Jones stains.
creatinine: vehicle, 1.41 6 0.27 mg/dL; SC58236, 1.19 6Glomerular sclerosis was assessed by counting in a
0.18 mg/dL; N 5 6, P 5 NS).blinded manner a minimum of 100 glomeruli per section.
Within one week after ablation, vehicle-treated ratsThe results are presented as the number of glomeruli
developed hypertension (systolic BP, 164 6 10 mm Hg;exhibiting either segmental or global sclerosis. Changes
N 5 7), while the increases in systolic BP were signifi-in the vascular and tubulointerstitial compartments were
cantly blunted in the enalapril-treated rats (Fig. 1C).also assessed blindly and recorded descriptively or semi-
In contrast, BP in rats administered SC58236 was notquantitatively.
significantly different than in vehicle-treated rats. ThereRenal cortex RNA was extracted by the acid guanid-
ium thiocyanate-phenol chloroform method, as described were no significant differences in systolic BP between
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Fig. 1. Physical and metabolic parameters of rats with subtotal renal
ablation. (A) Body weight. (B) Blood urea nitrogen (BUN). (C) Systolic
blood pressure. Symbols are: (h) vehicle; (r) enalapril (20 mg/kg body
wt/day); (d) SC58236 (10 mg/kg body weight/day); (m) enalapril 1
SC58236 (N 5 6 to 8 for each group).
rats administered enalapril or the combination of enala- Fig. 2A). Treatment of the remnant-kidney rats with
SC58236 for six weeks led to inhibition of proteinuriapril and SC58236 (Fig. 1C).
Following renal ablation, vehicle-treated rats mani- similar to that seen with enalapril (6 week, 30 6 2 mg/24
hours; N 5 7, P , 0.01 compared with vehicle). Therefested progressively increasing proteinuria. In agreement
with previous studies [21], enalapril treatment signifi- was not a discernible additive effect of simultaneous
treatment of enalapril and SC58236 (6 week, 34 6 2cantly inhibited increases in proteinuria during the six-
week period following ablation (6 week: vehicle, 47 6 mg/24 hours; Fig. 2A). In animals treated for 10 weeks,
SC58236 treatment also led to significant blunting of4 mg/24 hours vs. enalapril, 27 6 2; N 5 7, P , 0.01;
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animals were also less pronounced, and there was less
tubular atrophy and tubulointerstitial fibrosis (Fig. 3 E, F).
Compared with control animals, total renal cortical
renin mRNA expression was not significantly increased
in the remnant kidney at six weeks (Fig. 5). Renin mRNA
in the remnant kidney treated with SC58236 was mini-
mally lower than in the untreated rats. As expected, renin
mRNA increased with enalapril treatment, and SC58236
blunted the increased renin secondary to angiotensin-
converting enzyme (ACE) inhibition [22]. Increased
TGF-b1 mRNA expression in the remnant kidney were
blunted by treatment with SC58236 (Fig. 6A) at 10 weeks,
as were increases in the expression of type III collagen
mRNA (Fig. 6B) and type IV collagen mRNA (Fig. 6C).
DISCUSSION
The present studies demonstrate that chronic adminis-
tration of a selective COX-2 inhibitor significantly de-
creased proteinuria and inhibited development of glo-
merular sclerosis in rats with reduced functioning renal
mass. In our initial studies, SC58236-mediated decreases
in proteinuria were comparable to that seen with anFig. 2. Proteinuria in rats following subtotal renal ablation. Symbols
ACE inhibitor. Similarly, at six weeks following surgery,are: (h) vehicle; (r) enalapril (20 mg/kg body weight/day); (d) SC58236
(10 mg/kg body wt/day); (m) enalapril combined with SC58236 (N 5 the COX-2 inhibitor decreased glomerular injury to lev-
6 to 7, *P , 0.01).
els comparable to enalapril. Although the combination
of SC58236 and enalapril did not lead to reductions in
proteinuria different from that seen with either agent
alone, there did appear to be a trend toward furtherthe increases in proteinuria (10 week: vehicle, 77 6 4;
reduction in glomerular injury with combined therapySC58236, 50 6 4 mg/day; N 5 6, P , 0.01; Fig. 2B).
(Fig. 4A), although these differences did not reach statis-Following six weeks of treatment with vehicle, 6.0 6
tical significance. It is of interest that enalapril, alone or2.4% of glomeruli exhibited segmental sclerotic lesions
in combination with SC58236, led to significant decreases(N 5 6). Treatment with SC58236 significantly decreased
in systolic BP, in contrast to the lack of effect of SC58236,the incidence of segmental glomerulosclerosis (1.0 6
suggesting that any “renoprotective” effects seen with0.7%, N 5 7, P , 0.05 vs. vehicle), as did treatment with
the COX-2 inhibitor were not secondary to the modula-enalapril (0.6 6 0.4%, N 5 7, P , 0.05) and treatment
tion of systemic BP.with the combination of enalapril and SC58236 (0.2 6
Because the extent of structural injury was relatively0.2%, N 5 6, P , 0.05; Fig. 4A).
small at six weeks following renal ablation, we treatedIn remnant kidneys of rats treated with vehicle for 10
further animals with SC58236 or vehicle for up to tenweeks, many glomeruli (32.6 6 7.8%) exhibited segmen-
weeks and further confirmed that COX-2 inhibitiontal or global sclerotic changes (Figs. 3 and 4). Global
could significantly decrease proteinuria and retard struc-sclerosis was variable among animals, ranging from 0 to
tural renal injury. The present studies confirm and extend19%, with a mean of 6.7 6 2.9%. SC58236 treatment
the recent findings of Fujihara et al that prolonged treat-for 10 weeks significantly reduced the percentage of glo-
ment with a combination cyclooxygenase inhibitor/nitricmeruli exhibiting segmental or global sclerosis (10.9 6
oxide donor significantly decreased progression of glo-2.8%, N 5 6, P , 0.05; Fig. 4B). In the SC58236-treated
animals, the segmental sclerotic lesions were generally merular injury in rats with remnant kidneys [24]. How-
ever, in contrast to the studies of Fujihara et al, ourless pronounced than in the vehicle-treated animals and
were predominantly at the vascular pole (Fig. 3). Only studies used a highly selective inhibitor of COX-2,
thereby implicating prostanoids originating from this iso-1.3 6 0.8% of the glomeruli in the SC58236-treated
group were judged to be globally sclerotic. In vehicle- form in progression of structural glomerular damage fol-
lowing ablation of renal mass.treated animals, there were prominent vascular changes,
with medial thickening of interlobular and arcuate arter- In previous studies, we determined that COX-2 expres-
sion in the renal cortex of adult rats was localized to occa-ies and variable degrees of tubular atrophy and intersti-
tial fibrosis. The vascular changes in the SC58236-treated sional cortical thick ascending limb of Henle (cTALH)
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Fig. 3. Histology of kidney cortex 10 weeks after subtotal ablation. (A, C, and E ) Vehicle treated. (B, D, and F ) SC58236 treated. The vehicle-
treated kidneys demonstrate more segmental and global sclerosis, tubulointerstitial infiltrate, and tubular atrophy (A, B, E, and F, 3100; C and
D, 3200).
cells in the region of the macula densa [5]. With salt COX-1 expression. This increased COX-2 expression
was most prominent in the cTALH in the region of thedepletion, COX-2 expression increased significantly in
cTALH and in the macula densa [5, 11, 12]. Interestingly, macula densa. In addition, there was detectable COX-2
immunoreactivity in some glomeruli from remnant kid-we have also determined that within two weeks following
subtotal renal ablation, there were selective increases neys, with increased expression predominantly in vis-
ceral epithelial cells, as well as in occasional mesangialin renal cortical COX-2 mRNA and immunoreactive
protein expression, without significant alterations in cells [13].
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Fig. 6. Effect of COX-2 inhibition on expression of TGF-b1 (A), type
III collagen (B), and type IV collagen (C) in the remnant kidney. Lane
1, control. Lane 2, vehicle-treated remnant. Lane 3, SC58236-treated
remnant. Relative expression of GAPDH mRNA expression is provided
for comparison.
Glomeruli from remnant kidneys [19], as well as ani-
mals fed a high-protein diet [18, 25], demonstrated in-
Fig. 4. Percentage of glomeruli demonstrating segmental or global creased prostanoid production. These studies suggested
sclerosis at 6 weeks (A) or 10 weeks after subtotal ablation (B; *P , an increase in cyclooxygenase enzyme activity per se0.05).
rather than or in addition to increased substrate avail-
ability, since increases in prostanoid production were
noted when excess exogenous arachidonic acid was
added. In our recent studies, we determined that the
increased prostaglandin production in isolated glomeruli
from remnant kidneys was inhibited by a COX-2–
selective inhibitor but was not decreased by a COX-1–
selective inhibitor [13].
In cultured mesangial cells, “vasodilatory” prostaglan-
dins (PG), PGE2 and PGI2, inhibit proliferation and extra-
cellular matrix deposition [26–29], while “vasoconstrictive”
prostaglandins, PGF2a and thromboxane A2, stimulate pro-
liferation [30]. Therefore, it is possible that COX-2 inhi-
Fig. 5. Rat renal cortex renin mRNA expression. Lane 1, control. Lane bition in the remnant model may decrease production2, vehicle-treated remnant. Lane 3, enalapril-treated remnant. Lane 4,
of “prosclerotic” eicosanoids and cytokines from either in-SC58236-treated remnant. Lane 5, enalapril 1 SC58236-treated rem-
nant. Relative expression of glyceraldehyde-3-phosphate dehydrogen- filtrating inflammatory cells or intrinsic glomerular cells.
ase (GAPDH) mRNA expression is provided for comparison. Previous studies have demonstrated that thromboxane
synthase inhibitors retarded the progression of glomeru-
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losclerosis, with decreased proteinuria and glomerulo- glomerular capillary pressure (PGC) was not altered be-
sclerosis in rats with remnant kidneys, in association with cause both afferent and efferent arteriolar resistances
increased renal prostacyclin production and lower sys- increased [14]. In addition, NSAIDs have been reported
tolic BP [16, 17, 31, 32]. Schmitz et al confirmed increases to be effective in reducing proteinuria in patients with
in thromboxane B2 excretion and correlated decreased refractory nephrotic syndrome [40–43].
arachidonic and linoleic acid levels in the remnant kidney Defective autoregulation of renal blood flow caused
with increased thromboxane production, since the throm- by decreased myogenic tone of the afferent arteriole is
boxane synthase inhibitor U63557A restored fatty acid seen after either subtotal ablation or excessive dietary
levels and retarded progressive glomerular destruction protein and is corrected by inhibition of cyclooxygenase
[17]. Thromboxane has also been shown to stimulate activity [44, 45]. In these hyperfiltering states, tubulo-
mesangial cell matrix production by both TGF-b– glomerular feedback (TGF) is reset at a higher distal
dependent and TGF-b–independent pathways [33, 34]. tubular flow rate [46–48]. Such a resetting dictates that
Therefore, our findings that a selective COX-2 inhibitor afferent arteriolar vasodilation will be maintained in the
decreased mRNA expression of TGF-b1 and of types III face of increased distal solute delivery. It has previously
and IV collagen is consistent with an inhibition of throm- been shown that the alterations in TGF sensitivity after
boxane-mediated responses in the remnant kidney. a reduction in renal mass are prevented with the nonse-
Although studies with ACE inhibitors and angiotensin lective cyclooxygenase inhibitor indomethacin [49]. An
receptor blockers have indicated an important role for important role has been suggested for neuronal nitric
the renin-angiotensin system in the pathologic changes oxide synthase, which is localized to the macula densa,
occurring in the remnant kidney, the evidence suggesting in the vasodilatory component of TGF [50–52]. Of inter-
increased intrarenal renin expression in this model is est for the present studies, recent work by Ichihara et al
still controversial. In general, previous investigators have has determined that this neuronal nitric oxide synthase-
detected either no change or decreases in plasma renin mediated vasodilation is inhibited by the selective COX-2
and renal renin expression [35, 36], although renin ex- inhibitor NS398, suggesting that COX-2–mediated prost-
pression in the juxtaglomerular apparatus may be selec- anoids may be essential for arteriolar vasodilation [53].
tively increased in the glomeruli adjacent to the scarred It remains to be determined whether alterations in NO
area of the remnant kidney, suggesting that these glomer-
production might also contribute to the renoprotective
uli may be selectively hypoperfused [37]. In addition,
effects of COX-2 inhibition.increased intraglomerular renin expression has been de-
In conclusion, chronic administration of a COX-2 in-scribed in remnant glomeruli [38]. In our previous stud-
hibitor led to significant preservation of glomerular struc-ies, we could not demonstrate localization of the increased
ture and function in a rat model of renal ablation.macula densa COX-2 expression only to the “peri-scar”
Whether these ameliorative effects were due to modula-glomeruli [13]. In the present studies, total renal cortical
tion of inflammatory stimuli that may mediate cell injuryrenin mRNA was not increased in the remnant kidneys;
and alterations in matrix deposition or effects on glomer-there was a trend for a small decrease in renin expression
ular hemodynamics will require further study. It is cer-in the SC58236-treated rats, but its physiologic signifi-
tainly noteworthy that the decreases in renal injury werecance is unclear at present. As indicated in Figure 5, the
not the result of alterations in systemic BP, since theremnant kidneys did retain the ability to increase renin
same degree of hypertension was present in both vehicle-mRNA expression in response to ACE inhibition, and
and SC58236-treated animals. These studies suggest thatthe decreased renin expression in the enalapril-treated
COX-2 inhibitors may be tolerated and possibly evenrats administered SC58236 is similar to what we pre-
beneficial in patients with chronic renal insufficiency;viously reported in animals with intact kidneys [22].
however, further preclinical studies, as well as directedFinally, it should also be mentioned that cyclooxygen-
clinical trials, must be undertaken.ase-derived arachidonic acid metabolites are mediators
of altered renal hemodynamic function in response to in-
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